C59T mutation in exon 2 of monocytic leukemia‑associated antigen‑34 gene indicates a high risk of recurrence of acute myeloid leukemia

Lei,Bo; Chen,Yinxia; He,Aili; Luo,Jing; Zhang,Pengyu; Zhou,Fuling; Liu,Jie; Meng,Xin; Wang,Jing; Zhang,Wanggang

doi:10.3892/ol.2017.6110

C59T mutation in exon 2 of monocytic leukemia‑associated antigen‑34 gene indicates a high risk of recurrence of acute myeloid leukemia

Authors:
- Bo Lei
- Yinxia Chen
- Aili He
- Jing Luo
- Pengyu Zhang
- Fuling Zhou
- Jie Liu
- Xin Meng
- Jing Wang
- Wanggang Zhang
View Affiliations

Affiliations: Department of Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shanxi 710004, P.R. China, Department of Neurology, 451 Hospital of People's Liberation Army, Xi'an, Shaanxi 710054, P.R. China
Published online on: May 2, 2017 https://doi.org/10.3892/ol.2017.6110
Pages: 55-62
Copyright: © Lei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Monocytic leukemia‑associated antigen‑34 (MLAA‑34) is a novel monocytic leukemia‑associated antigen and a candidate oncogene. The aim of the present study was to investigate the involvement of the MLAA‑34 gene in acute myeloid leukemia (AML). MLAA‑34 expression level, chromosome location, gene copy number and single nucleotide polymorphisms (SNPs) of 40 patients with AML and 5 healthy volunteers were analyzed by reverse transcription‑polymerase chain reaction, fluorescence in situ hybridization and DNA sequencing. The effects of MLAA‑34 mutation on overall survival (OS) and progression‑free survival (PFS) of patients with AML were also analyzed. MLAA‑34 was significantly upregulated in patients with AML when compared with volunteer controls, and this upregulation was associated with a C59T SNP site located in the second exon of MLAA‑34. MLAA‑34 was mapped to 13q14.2 and no translocation was observed in patients with AML. In addition, this SNP site is affinitive to the well‑known molecular markers of AML, including Fms‑like tyrosine kinase 3 and DNA methyltransferase 3A, as well as extramedullary lesions, periphery leukocyte numbers, remission and cytogenetic abnormalities of patients with AML. Patients with AML with MLAA‑34 C59T mutations had significantly shorter OS and PFS times compared with that of patients without C59T mutations. The present findings indicated that the MLAA‑34 C59T mutation was a high‑risk factor for recurrence of AML, and may be a candidate target for AML therapy.

View Figures

View References

1	Lindblad O, Chougule RA, Moharram SA, Kabir NN, Sun J, Kazi JU and Rönnstrand L: The role of HOXB2 and HOXB3 in acute myeloid leukemia. Biochem Biophys Res Commun. 467:742–747. 2015. View Article : Google Scholar : PubMed/NCBI
2	Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, Fischer R, Tur MK and Barth S: Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther. 7:2924–2932. 2008. View Article : Google Scholar : PubMed/NCBI
3	Tettamanti S, Marin V, Pizzitola I, Magnani CF, Attianese GM Giordano, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, et al: Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J haematol. 161:389–401. 2013. View Article : Google Scholar : PubMed/NCBI
4	Mensen A, Oh Y, Becker SC, Hemmati PG, Jehn C, Westermann J, Szyska M, Göldner H, Dörken B, Scheibenbogen C, et al: Apoptosis susceptibility prolongs the lack of memory B cells in acute leukemic patients after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 21:1895–1906. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zhang PY, Zhang WG, He AL, Wang JL and Li WB: Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34. Cancer Immunol Immunother. 58:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
6	Goswami M and Hourigan CS: Novel antigen targets for immunotherapy of acute myeloid leukemia. Curr Drug Targets. 18:296–303. 2017. View Article : Google Scholar : PubMed/NCBI
7	Sykes DB, Haynes MK, Waller A, Garcia M, Urso U, Gouveia KE, Sklar L, Lewis TA, Dandapani S, Munoz B, et al: Identifying small molecules that overcome differentiation arrest in acute myeloid leukemia. Oncologist. 17:32012.PubMed/NCBI
8	Greiner J, Döhner H and Schmitt M: Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica. 91:1653–1661. 2006.PubMed/NCBI
9	Zhao J, He A, Zhang W, Meng X and Gu L: Quantitative assessment of MLAA-34 expression in diagnosis and prognosis of acute monocytic leukemia. Cancer Immunol Immunother. 60:587–597. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatler K, Bowen DT, Burnett AK, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 98:1752–1759. 2001. View Article : Google Scholar : PubMed/NCBI
11	Chen G, Zhang W, Cao X, Li F, Liu X and Yao L: Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res. 29:503–509. 2005. View Article : Google Scholar : PubMed/NCBI
12	Zhang WJ, Zhang WG, Zhang PY, Cao XM, He AL, Chen YX and Gu LF: The expression and functional characterization associated with cell apoptosis and proteomic analysis of the novel gene MLAA-34 in U937 cells. Oncol Rep. 29:491–506. 2013.PubMed/NCBI
13	Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G and Caligiuri MA: Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 29:2382–2389. 2015. View Article : Google Scholar : PubMed/NCBI
14	Park SH, Lee HJ, Kim IS, Kang JE, Lee EY, Kim HJ, Kim YK, Won JH, Bang SM, Kim H, et al: Incidences and prognostic impact of c-KIT, WT1, CEBPA, and CBL mutations, and mutations associated with epigenetic modification in core binding factor acute myeloid leukemia: A multicenter study in a Korean population. Ann Lab Med. 35:288–297. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sawyers CL: Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell. 1:413–415. 2002. View Article : Google Scholar : PubMed/NCBI
16	Berenstein R, Blau IW, Suckert N, Baldus C, Pezzutto A, Dörken B and Blau O: Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia. J Exp Clin Cancer Res. 34:552015. View Article : Google Scholar : PubMed/NCBI
17	Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, van Delft FW, Treleaven J, Georgiades P, et al: Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood. 126:1214–1223. 2015. View Article : Google Scholar : PubMed/NCBI
18	Yoon JH, Kim HJ, Jeon YW, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, et al: Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. Genes Chromosomes Cancer; 2015
19	Fulton KM and Twine SM: Immunoproteomics: Methods and protocols. Methods Mol Biol New York: Humana Press, Springer; pp. 10612013
20	Yohe S: Molecular genetic markers in acute myeloid leukemia. J Clin Med. 4:460–478. 2015. View Article : Google Scholar : PubMed/NCBI
21	Annesley CE and Brown P: Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol. 6:61–79. 2015. View Article : Google Scholar : PubMed/NCBI
22	Chessells JM, Harrison CJ, Kempski H, Webb DK, Wheatley K, Hann IM, Stevens RF, Harrison G and Gibson BE: MRC Childhood Leukaemia working party: Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: Report from the MRC childhood leukaemia working party. Leukemia. 16:776–784. 2002. View Article : Google Scholar : PubMed/NCBI
23	Bolkun L, Lemancewicz D, Jablonska E, Szumowska A, Bolkun-Skornicka U, Ratajczak-Wrona W, Dzieciol J and Kloczko J: The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: Correlation with biological and clinical features. Ann Hematol. 94:35–43. 2015. View Article : Google Scholar : PubMed/NCBI
24	Qian L, Zhang W, Zhang P, Lei B, Wang X, Wang M, Bai J and He A: The anti-apoptosis effect of MLAA-34 in leukemia and the β-catenin/T cell factor 4 protein pathway. Am J Transl Res. 7:2270–2278. 2015.PubMed/NCBI